Suppressing HER2/neu-mediated cell transformation by transcriptional repressors

Breast Disease

Volumn 11, Issue , 2000, Pages 133-144

  Hung, M C ^a   Wang, S C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CATION; CHOLESTEROL DERIVATIVE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; LIPOSOME; TRANSCRIPTION FACTOR; TYROSINE KINASE RECEPTOR; VIRUS LARGE T ANTIGEN; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CELL TRANSFORMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; MOUSE; NONHUMAN; ONCOGENE NEU; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RAT; SIMIAN VIRUS 40; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0033853474     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-1999-11112     Document Type: Article

References (108)

1. The neu oncogene encodes an epidermal growth factor receptor-related protein
2. Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles
3. Similarity of protein encoded by the human c-erbB-2 gene to the epidermal growth factor receptor
4. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
5. Heregulin induces tyrosine phosphorylation of HER4/p180 erbB-4
6. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
7. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3
8. The erbB-3 gene product is a receptor for heregulin
9. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in NIH3T3 cells
10. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
11. Amplification of the proto-neu gene facilities oncogenic activation by a single point mutation
12. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo
13. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
14. Cell cycle-dependent regulation of p185neu: A relationship between disruption of this regulation and transformation
15. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
16. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
17. Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30 year follow-up
18. Prognostic importance of c-erbB-2 expression in breast cancer
19. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease
20. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer
21. Expression of the neu gene-encoded protein (p185neu) in human non-small cell carcinomas of the lung
22. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer
23. Amplification, overexpression, and rearrangement of the c-erbB-2 proto-oncogene in primary human stomach carcinomas
24. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma
25. Enhanced chemoresistance by elevation of the level of p185neu in HER2/neu transfected human lung cancer cells
26. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor
27. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
28. Overexpression of both p185c-erbB-2 and p170mdr-1 renders breast cancer cells highly resistant to taxol
29. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
30. Overexpression of erbB2 blocks Taxol-induced apoptosis by upregulation of p21cip1 which inhibits p34cdc2 kinase
31. Mechanisms of deregulated HER2/nue expression in breast cancer cell lines
32. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma
33. Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene
34. Cloning and characterization of the mouse neu promoter
35. Regulation of HER-2/neu gene expression
36. Identification and characterization of a novel enhancer for the rat neu promoter
37. Repressed expression of the HER-2/neu/c-erbB-2 proto-oncogene by the adenovirus E1A gene products
38. Adenovirus Type 5 E1A products acts as transformation suppressors of the neu oncogene
39. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer
40. Transcriptional repression of the neu proto-oncogene by the adenovirus 5 E1A gene products
41. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model
42. Safety studies of the intraperitoneal injection of E1A-liposome complex in mice
43. Potentiation of cationic liposome-mediated gene delivery by polycations
44. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans
45. Liposome-mediated E1A gene transfer as therapy for ovarian cancers that overexpress HER-2/neu
46. HER-2/neu-targeting via adenovirus-mediated E1A delivery in an animal model
47. Manual for staging of cancer Philadelphia
48. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer
49. Adenovirus promoters and E1A transactivation
50. Molecular biology of tumor viruses
51. Differential transformation of primary human embryo retinal cells by adenovirus E1A regions and combination of E1A (+) ras
52. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
53. Complete transformation by adenovirus 2 requires both E1A proteins
54. Molecular themes in oncogenesis
55. Role of adenovirus type 5 and 12 early region 1B tumor antigens in oncogenic transformation
56. Re-expression of neu-encoded oncoprotein counteracts the tumor-suppressing activity of E1A
57. Adenovirus E1A-mediated negative control of genes activated during F9 differentiation
58. The E1A gene of adenovirus type 2 reduces the metastatic potential of ras-transformed rat embryo cells
59. Antioncogenic effect of adenovirus E1A in human tumor cells
60. Adenovirus E1A-mediated tumor suppression by a c-erbB2/neu-independent mechanism
61. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo
62. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis
63. Inhibition of nuclear factor-kappa B activity is involved in E1A-mediated sensitization of radiation-induced apoptosis
64. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B
65. Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms
66. T antigen is bound to a host protein in SV40-transformed cells
67. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
68. The transformation activity of simian virus 40 large tumor antigen
69. Negative regulation of the neu promoter by the SV40 large T antigen
70. In vitro mutagenesis of a putative DNA binding domain of SV40 large T
71. A role for the ETS domain transcription factor PEA3 in myogenic differentiation
72. ERM, a PEA3 subfamily of Ets transcription factors, can cooperate with c-Jun
73. The ETS-domain: A new DNA-binding motif that recognizes a purine-rich core DNA sequence
74. The ets multigene family is conserved throughout the Metazoa
75. Evolution of the ets gene family
76. A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells
77. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer
78. Expression of the PEA3 group of EST-related transcription factors in human breast cancer cells